Evidence that cytokines play a role in rheumatoid arthritis

被引：945

作者：

Brennan, Fionula M. ^{[1
]}

McInnes, Iain B. ^{[2
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London W6 8LH, England

[2] Univ Glasgow, Ctr Rheumat Dis, Div Immunol Infect & Inflammat, Glasgow, Lanark, Scotland

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2008年 / 118卷 / 11期

关键词：

D O I：

10.1172/JCI36389

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

A large number of cytokines are active in the joints of patients with rheumatoid arthritis (RA). It is now clear that these cytokines play a fundamental role in the processes that cause inflammation, articular destruction, and the comorbidities associated with RA. Following the success of TNF-alpha blockade as a treatment for RA, other cytokines now offer alternative targets for therapeutic intervention or might be useful as predictive biomarkers of disease. In this Review, we discuss the biologic contribution and therapeutic potential of the major cytokine families to RA pathology, focusing on molecules contained within the TNF-alpha, IL-1, IL-6, IL-23, and IL-2 families.

引用

页码：3537 / 3545

页数：9

共 130 条

[1] Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 [J].

Aggarwal, S ;

Ghilardi, N ;

Xie, MH ;

de Sauvage, FJ ;

Gurney, AL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (03) :1910-1914

[2] Interleukin 6 is required for the development of collagen-induced arthritis [J].

Alonzi, T ;

Fattori, E ;

Lazzaro, D ;

Costa, P ;

Probert, L ;

Kollias, G ;

De Benedetti, F ;

Poli, V ;

Ciliberto, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (04) :461-468

[3] Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis [J].

Andersson, A. K. ;

Feldmann, M. ;

Brennan, F. M. .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2008, 68 (01) :103-111

[4] Interleukin-1 receptor antagonist: Role in biology [J].

Arend, WP ;

Malyak, M ;

Guthridge, CJ ;

Gabay, C .

ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :27-55

[5]

BALDASSARE A, 2007, AM COLL RHEUM ANN SC

[6] The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders [J].

Barksby, H. E. ;

Lea, S. R. ;

Preshaw, P. M. ;

Taylor, J. J. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 149 (02) :217-225

[7] Targeting interleukin-15 in patients with rheumatoid arthritis - A proof-of-concept study [J].

Baslund, B ;

Tvede, N ;

Danneskiold-Samsoe, B ;

Larsson, P ;

Panayi, G ;

Petersen, J ;

Petersen, LJ ;

Beurskens, FJM ;

Schuurman, J ;

van de Winkel, JGJ ;

Parren, PWHI ;

Gracie, JA ;

Jongbloed, S ;

Liew, FY ;

McInnes, IB .

ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2686-2692

[8] Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells [J].

Batten, Marcel ;

Li, Ji ;

Yi, Sothy ;

Kljavin, Noelyn M. ;

Danilenko, Dimitry M. ;

Lucas, Sophie ;

Lee, James ;

de Sauvage, Frederic J. ;

Ghilardi, Nico .

NATURE IMMUNOLOGY, 2006, 7 (09) :929-936

[9] Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12 [J].

Becher, B ;

Durell, BG ;

Noelle, RJ .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (04) :493-497

[10] IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis [J].

Becher, B ;

Durell, BG ;

Noelle, RJ .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (08) :1186-1191

← 1 2 3 4 5 6 7 8 9 10 →